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Introduction: Pulmonary arterial hypertension (PAH) is a progressive and ultimately fatal disease 
affecting ~6 people per million, per year (1). Recent studies have reported mutations in the two-pore 
domain potassium (K2P) channel TASK-1 (KCNK3) giving rise to PAH (2). Treprostinil is a stable 
prostacyclin analogue often administered as a therapy in PAH, to keep blood vessels open. It’s 
mode of action is thought to occur through an interaction with prostanoid receptors, DP2 EP2 and IP 
(3). Patients undergoing continuous subcutaneous treprostinil infusion can often exhibit severe pain 
at the site of delivery (4). In this study we investigate the action of treprostinil on TASK-1 and on two 
other K2P channels, TREK-1 (KCNK2) and TREK-2 (KCNK10), which regulate the excitability of 
sensory neurons and are implicated in pain (5).  
Method: Using the whole-cell patch-clamp technique, currents were measured through human 
TASK-1, TREK-1 and TREK-2 channels transiently expressed in tsA201 cells. TASK-1 was also co-
expressed with prostanoid receptors (IP, DP2 and EP2). Data are expressed as mean ± SEM (n = 
cells) of current measured at -40 mV and mean % change ± SEM (n = cells), with statistical analysis 
performed using a paired t-test.  
Results: Acute application of treprostinil (1 µM) on cells expressing TASK-1 channels had no effect 
on current (control: 234 ± 80 pA; treprostinil: 240 ± 53 pA (n = 5); p > 0.05). Co-expression of TASK-
1 with various prostanoid receptors, followed by acute application of treprostinil (1 µM) resulted in 
varying effects on TASK-1 current. In cells expressing WT TASK-1 and IP receptors, the average 
TASK-1 current significantly decreased by 50% in the presence of treprostinil (control: 333 ± 82 pA; 
treprostinil (1 µM): 173 ± 46 pA, n = 6, p < 0.05). Whilst co-expression of TASK-1 with EP2 receptors 
saw a 30% increase in TASK-1 current (control: 294 ± 65 pA; treprostinil (1 µM): 368 ± 78 pA, n = 
8, p<0.05). Co-expression of TASK-1 with DP2 receptors saw no significant change (3%) in TASK-
1 current (control: 387 ± 45 pA; treprostinil (1 µM): 398 ± 54 pA, n = 5, p > 0.05). Interestingly, 
treprostinil had a potent inhibitory effect on the TREK channels in the absence of prostanoid 
receptors: TREK-1 WT (80 ± 8%, n = 5; p<0.05) and TREK-2 WT (59 ± 9%, n = 5; p < 0.05). 
Conclusion: In this study, acutely applied treprostinil does not appear to have a direct action on the 
TASK-1 channel itself, instead its effects appear to occur through the activation of prostanoid 
receptors and their associated signalling pathways. Conversely, treprostinil demonstrates a direct 
inhibitory effect on TREK-1 and TREK-2 channels. This effect of treprostinil may explain infusion 
site pain, a common side-effect of patients on subcutaneous treatment (4). Acute enhancement of 
these channels at the infusion site could therefore help to reduce discomfort in PAH patients. 
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